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A 71-year-old male was referred from his general 
practitioner to the Oral Medicine Clinic at the University 
of the Western Cape, Oral Health Centre, Tygerberg 
campus, on account of a six-week history of recurrent 
oral ulceration. 
The patient reported that his mouth and throat were 
painful and he had difficulty in swallowing food. Initially, 
the ulcers had persisted over the two weeks following the 
prescription of Dynexan®, Augmentin 1g BDS for 5 days, 
Andolex C® and Mucain mouthwash®, by his general 
practitioner. Subsequent referral to an ENT surgeon had 
resulted in confirmation of an extra-oesophageal reflux 
component. A PPI (proton-pump inhibitor), Gastriwin®, 
was prescribed. 
The patient disclosed that he had Type II diabetes, 
hypertension and had suffered a cerebrovascular 
accident (stroke) two years previously. Questioning by the 
ENT surgeon revealed that the patient had consulted a 
dermatologist who had prescribed methotrexate (MTX) 
to treat psoriasis. The patient did not use supplementary 
folic acid. The outcome of blood investigations, requested 
by the ENT surgeon, revealed bone marrow suppression 
as a result of the methotrexate usage. The patient was 
referred to his dermatologist with the recommendation 
that the medication be supplemented with folic acid.
Extra oral examination revealed the presence of a 10 mm 
scaly patch, surrounded by an erythematous margin, on 
the patient’s right hand. Similar lesions were observed on 
the extensor surfaces of both legs. 
The patient was edentulous with a loss of vertical 
dimension and did not wear any dentures. Diffuse, ill-
defined erosions and ulcerations were present bilaterally 
on the buccal mucosa, upper and lower labial mucosa. 
The surfaces of the lesions were white to yellow in colour. 
The posterior soft palate had areas of irregular ulcerations 
and erosions, which contributed to the difficulty in 
swallowing.
A differential diagnosis of methotrexate-induced oral 
ulceration was proposed. The condition was exacerbated by 
the lack of folic acid supplementation, which contributed to 
the subsequent bone marrow suppression. The lymphocyte 
count, red cell count and platelet levels were 0.5x10E9/L, 2.8 
x10E12/L and 63x10E9/L respectively (Table 1).
DISCUSSION
Oral ulceration is a common side effect of various 
drugs.1,2 Direct contact may cause local hypersensitivity 
or chemical burn, or, less frequently, the complication is 
part of a complex reaction with cutaneous or systemic 
manifestations.1
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ACRONYMS
MTX:  Methotrexate 
Blood Investigation Result Normal Range
Lymphocyte count 0.5 x10E9/L 1.00-4.00 x10E9/L 
Red blood cell count 2.8 x10E12/L 4.5-5.9 x10E12/L
Platelet levels 63 x10E9/L 140-420 x10E9/L
Hemoglobin 7.9 g/dL 11.5-16 g/dL
Hematocrit 0.25 L/L 0.40-0.50 L/L
Figure 1: Methotrexate-induced mucosal erosions/ulcerations on the right 
buccal mucosa
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Drug induced oral ulcers are resistant to conventional 
therapies; but will heal rapidly following withdrawal 
or reduction of the dose of the suspect medication.1 
Recognition of the cause and subsequent diagnosis of 
these ulcerations is usually difficult, especially in patients 
on multiple drug regimens.1,3
 
Medications likely to induce solitary oral ulcers are 
commonly prescribed in the management of rheumatoid, 
cardiac and psychiatric conditions.1-3 (Table 2).
MTX is an antimetabolite, antifolate agent developed 
in 1948, used to treat certain forms of cancer. It is also 
commonly used to treat rheumatoid arthritis in both adults 
and juveniles and severe psoriasis.4,5 MTX interrupts the 
synthesis of both DNA and RNA and slows or stops the 
growth of rapidly dividing cells, including mucosal, cancer 
and bone marrow cells. MTX induces a deficiency of folate-
dependent co-enzymes and suppresses the immune 
system.4,6 MTX is a bicarboxylic acid, a folic acid analogue 
that inhibits dihydrofolate reductase enzyme. The latter is 
required to reduce folate to an active form, which acts as 
a co-factor in the production of nucleic acids essential for 
DNA synthesis. Inhibition of this enzyme by MTX causes 
a reduction in DNA formation and cell turnover and is 
responsible for both its therapeutic and the more common 
side effects, such as myelosuppression and mucositis.7,8
Psoriasis is a chronic, inflammatory, non-contagious 
skin condition usually affecting the skin of the elbows, 
knees, and scalp.9,10 The cells in the superficial skin layer 
multiply more quickly than normal, causing thickened 
areas of skin, and producing thick scaling plaque. It has 
a variable course with periodic periods of remission and 
exacerbation.9 Both biologic and non-biologic agents 
are used in its treatment. Non-biologics, such as MTX, 
suppress the immune system and are considered first-
line treatments.11 Biologics target certain aspects of 
the immune system contributing to the pathogenesis of 
psoriasis.11,12 These agents are generally well tolerated 
and limited outcome data have determined biologics to 
be safe for long-term use in moderate to severe plaque 
psoriasis. However, biologics have been linked to risks of 
immunosuppression, serious infections and malignancy, 
both cutaneous and lymphoproliferative.11-13
 
Regular blood and liver function tests are required for 
patients undergoing systemic treatment to monitor the 
toxicities of these medications, all of which must be 
avoided in pregnancy.4,10 
CASE BOOK http://dx.doi.org/10.17159/2519-0105/2017/v72no7a6
Figure 2: Diffuse erosions and ill-deﬁned ulcerations on the left side buccal 
mucosa. The surface of the lesion was white to yellow in colour.  
Figure 3: Diffuse erosions and ill-deﬁned ulcerations on  lower labial mucosa.
Figure 4: Diffuse erosions and ill-deﬁned ulcerations on upper labial mucosa. Figure 5: Posterior soft palate demonstrated irregular ulceration and erosions.
Table 2: Drugs commonly implicated in oral ulceration
Rheumatology NSAI and long-term rheumatoid arthritis 
therapy
Azathioprine, methotrexate, penicillamine, 
gold compounds, tiopronin
Cardiology  Angiotensin-converting-enzyme inhibitors. Angiotensin 2-receptor antagonist Captopril, enalapril.Losartan, anti-angorous as nicorandil
Psychiatry Antidepressants Fluoxetine, lithium
HIV AIDS therapy Foscarnet, zalcitabine
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Oral ulceration is reported in 14% of patients on long-term, 
low-dose MTX treatment.14 The lesions may be caused by 
a lack of folic acid supplementation or an over-dosage 
of the MTX drug.14 Whilst the lesions are aggravated by 
chronic drug administration, they will disappear three 
weeks after suspension of the MTX administration. This 
adverse effect of MTX is mostly dose-dependent and 
usually occurs due to an accidental over dosage.7
Oral side effects are of importance to the patient not 
only because of the associated pain, but also because 
it affects the ability to eat. This aggravates the folate 
deficiency, causes weight loss and leads to a general 
weakening of health.7 Folic acid supplementation can 
reduce MTX-induced mucosal and gastrointestinal side 
effects by 79%.6
Most of the cases of ulceration induced by methotrexate 
have been described in patients treated with low-dose 
(7.5-25mg/wk) instead of a higher dose of methotrexate 
(100-250mg/m2/wk), probably because hyperproliferative 
psoriatic plaques are more susceptible to the influence of 
folate antagonism.15,18
One of the primary toxic effects of methotrexate is 
myelosuppression. MTX suppressed hematopoiesis 
has been confirmed to cause anemia, aplastic anemia, 
leukopenia, pancytopenia, neutropenia, thrombocytopenia, 
lymphadenopathy, and lymphoproliferative disorders.16 
MTX is thus contraindicated in patients with low 
hematologic cell counts or pre-existing myelosuppression. 
Regular monitoring of a complete blood count (CBC) is 
compulsory and some cases may require temporary 
discontinuation of the therapy. In addition, folate therapy 
or leucovorin rescue may prevent or palliate side effects.17
Low dose methotrexate is increasingly being administered 
in the control of psoriasis. It is generally an effective 
and safe medication, with oral ulceration being its most 
common side effect. Oral ulceration may be due to dosage 
error or folate deficiency and these problems should be 
clarified in patients who present with oral ulceration while 
using methotrexate.16
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